Hylands Assists CorrectSequence Therapeutics in Completing New Series Financing of Nearly RMB 300 Million

Recently, CorrectSequence (Shanghai) Biotechnology Co., Ltd (hereinafter referred to as "CorrectSequence Therapeutics") has completed the latest series of financing of RMB 300 million. As the legal counsel of CorrectSequence Therapeutics, Hylands has provided legal services for the overall financing series.

CorrectSequence Therapeutics is a hi-tech biopharmaceutical enterprise applying novel gene editing technology (base editing) to treat human diseases, with a focus on biotechnology innovation and the development of breakthrough therapies for the benefit of human health. Based on the research progress of the founding research team from Shanghai University of Science and Technology, Chinese Academy of Sciences and Wuhan University, and by pooling scientific research talents from top national and foreign colleges, universities and research institutes, as well as professional teams with years of experience in famous pharmaceutical companies at home and abroad, CorrectSequence Therapeutics is committed to building a top-notch domestic and international gene editing therapy platform.

Hylands has been engaged in the medical and health care services for many years with continuous efforts. Furthermore, with its extensive experience in intellectual property, corporate and investment, private equity, pharmaceutical and health care services, Hylands has continued to safeguard CorrectSequence Therapeutics in various aspects such as financing transactions and scientific research cooperation. In the future, Hylands will further assist CorrectSequence Therapeutics in its efforts to combat human genetic diseases and benefit human health. The legal service team for the Project consisted of Partner Han ZHOU, Partner Jie LI, Partner Wenjie JIANG, and Lawyer Xuan WANG.